The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
26 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $17,147,667 in first-year total cost, median $727,597.
Most frequent study sections
- Special Emphasis Panel[ZAI1 JHM-X (S3)]3
- Special Emphasis Panel[ZAI1 LG-W (S1)]2
- Special Emphasis Panel[ZAI1 MSA-W (M1)]2
- Special Emphasis Panel[ZAI1 RG-W (S2)]2
- Special Emphasis Panel[ZAI1 ZL-W (J2)]2
Most frequent institutions
- COLUMBIA UNIVERSITY HEALTH SCIENCES2
- PURDUE UNIVERSITY2
- STANFORD UNIVERSITY2
- EMORY UNIVERSITY1
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm1R01AI158467-01 | GLENN, JEFFREY S | STANFORD UNIVERSITY, CA | $799,024 | ZAI1 |
| 2021 | Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-21R01AI159945-01 | BAKER, SUSAN C. | LOYOLA UNIVERSITY CHICAGO, IL | $789,887 | ZAI1 |
| 2021 | Advancing the development of a novel class of small molecules for treating pan-coronavirus infections1R01AI158569-01 | EINAV, SHIRIT | STANFORD UNIVERSITY, CA | $779,425 | ZAI1 |
| 2021 | Small Molecule Inhibitors Against 3C-Like Protease of SARS-CoV-21R01AI161085-01 | CHANG, KYEONG-OKGROUTAS, WILLIAM CONSTANTINEPERLMAN, STANLEY | KANSAS STATE UNIVERSITY, KS | $774,037 | ZAI1 |
| 2021 | Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-21R01AI160961-01 | MOSCONA, ANNE | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $773,390 | ZAI1 |
| 2021 | Role and Mitigation of Inflammasomes and Inflammation During COVID-191R56AI158314-01 | KOLLER, BEVERLY HTING, JENNY P | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $768,215 | ZAI1 |
| 2021 | Revising Anti-coronavirus Compounds to Enhance Activity and Optimize Delivery1R01AI161348-01 | HOSTETLER, KARL YSCHOOLEY, ROBERT TURNER | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $766,165 | ZAI1 |
| 2021 | SARS-CoV-2 protease inhibitors for treating COVID-191R01AI158649-01 | GHOSH, ARUN KMESECAR, ANDREW D | PURDUE UNIVERSITY, IN | $750,974 | ZAI1 |
| 2021 | Fusion inhibitors that block host-to-host transmission of SARS-CoV-21R01AI160953-01 | DE SWART, RIK LPOROTTO, MATTEO | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $750,151 | ZAI1 |
| 2021 | Broad-spectrum therapeutics against SARS-CoV-2 3CL protease1R01AI161570-01 | FITZPATRICK, ELIZABETH ANNKOVARI, LADISLAU CHRISTOPHERSCHINAZI, RAYMOND FELIX | EMORY UNIVERSITY, GA | $681,379 | ZAI1 |
| 2021 | Development and characterization of engineered therapeutic antibodies against SARS-CoV-21R01AI161374-01 | AMARASINGHE, GAYA K. | WASHINGTON UNIVERSITY, MO | $667,277 | ZAI1 |
| 2021 | Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy1R01AI159182-01 | CAVACINI, LISA AFITZGERALD, KATHERINE A.SCHIFFER, CELIA A.WANG, YANG | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $664,782 | ZAI1 |
| 2021 | Structure, function, and inhibition of the SARS-CoV-2 replication-transcription complex1R01AI161278-01 | CAMPBELL, ELIZABETH ADARST, SETH A. | ROCKEFELLER UNIVERSITY, NY | $638,072 | ZAI1 |
| 2021 | Mechanism-based Targeting of the RNA Processing Machinery of SARS-CoV-21R01AI161363-01 | GUPTA, YOGESH K | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $608,161 | ZAI1 |
| 2021 | The cellular mechanisms of immunological memory development in COVID-19 patients1R56AI159536-01 | CUI, WEIGUO | VERSITI WISCONSIN, INC., WI | $428,542 | ZAI1 |
| 2021 | Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals1R01AI158775-01 | WANG, JUN | UNIVERSITY OF ARIZONA, AZ | $278,287 | ZAI1 |
| 2020 | Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronaviruses1R01AI157975-01 | DU, LANYINGLI, FANGPERLMAN, STANLEY | NEW YORK BLOOD CENTER, NY | $832,650 | ZAI1 |
| 2020 | Comprehensive assessment of SARS-CoV-2-reactive antibodies in human milk to determine their potential as a COVID-19 therapeutic and as a means to prevent infection of breastfed babies1R01AI158214-01 | POWELL, REBECCA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $793,353 | ZAI1 |
| 2020 | Novel delivery platform and antigen design for an effective COVID-19 vaccine1R01AI158177-01 | MITTAL, SURESH K | PURDUE UNIVERSITY, IN | $792,476 | ZAI1 |
| 2020 | Developing a Multi-epitope Pan-Coronavirus Vaccine1R01AI158060-01 | BENMOHAMED, LBACHIR | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $745,410 | ZAI1 |
| 2020 | Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic1R01AI158013-01 | GANDHI, MONICASPINELLI, MATTHEW A. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $709,784 | ZAI1 |
| 2020 | Overriding the Immune Evasion Tactics of Coronavirus1R01AI158552-01 | WARE, CARL F | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $617,996 | ZAI1 |
| 2020 | Development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity, specificity and ability to provide rapid results1R01AI158068-01 | HOGAN, MICHAEL E. | PATHOGENDX, AZ | $502,149 | ZAI1 |
| 2020 | Coronavirus RNA synthesis by multicomponent protein machines1R01AI158463-01 | KIRCHDOERFER, ROBERT N | UNIVERSITY OF WISCONSIN-MADISON, WI | $437,931 | ZAI1 |
| 2020 | Viral and immune-mediated CNS pathology during SARS-CoV-2 infection1R01AI157488-01 | FARHADIAN, SHELLIIWASAKI, AKIKO | YALE UNIVERSITY, CT | $417,822 | ZAI1 |
| 2020 | Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection1R01AI158154-01 | CHENG, GENHONG | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $380,328 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.